Bailie G R, Rasmussen R, Hollister A, Eisele G
Department of Pharmacy Practice, Albany College of Pharmacy, New York 12208.
Clin Nephrol. 1990 May;33(5):252-4.
Eighty-one patients were placed either on the O-set (39) or the UVXD germicidal system (42). Total experience was 13.7 +/- 8.0 and 17.8 +/- 14.8 months, respectively. There were 48 and 85 new episodes of peritonitis in 24 and 28 patients, respectively, and an additional 11 and 28 episodes of relapse or probable relapse. The peritonitis rate was 1 episode each 11.14 and 8.83 patient months, which was not significantly different. There was no significant difference between the 2 groups in terms of the mean numbers of peritonitis-free days (393.7 versus 503.8) or in the mean time to the first episode of peritonitis (6.60 versus 6.54 months). The odds ratio of relative risk of peritonitis with the two systems was 1:1.17 (O-set:UVXD). There appears to be no difference in ability of the two systems to prevent peritonitis.
81名患者被分为两组，分别采用O型装置（39例）或UVXD杀菌系统（42例）。总治疗时长分别为13.7±8.0个月和17.8±14.8个月。分别有24例和28例患者出现48次和85次新的腹膜炎发作，另外还有11次和28次复发或可能复发的情况。腹膜炎发生率分别为每11.14个和8.83个患者月出现1次发作，两者无显著差异。两组在无腹膜炎天数的平均值（393.7天对503.8天）或首次发生腹膜炎的平均时间（6.60个月对6.54个月）方面均无显著差异。两种系统发生腹膜炎相对风险的比值比为1:1.17（O型装置:UVXD）。两种系统预防腹膜炎的能力似乎没有差异。
